IP Library Granted Patent US 9,918,880
Granted Patent B2
US 9,918,880 · App. 14/252,644 · Granted Mar 20, 2018

Systems for providing fluid flow to tissues

Inventors: Larry D. Swain (San Antonio, TX); Michael E. Manwaring (San Antonio, TX); Douglas A. Cornet (Charlottesville, VA); Braden King-Fung Leung (San Antonio, TX)
Assignee: KCI Licensing, Inc.
A61F13/00068A61F2/2846A61F13/00063A61K38/18A61K38/19A61K38/22A61M1/0088A61M27/00A61M37/00A61M37/0092A61N5/062A61B17/88A61F2002/2835A61F2002/30784A61F2002/368A61F2013/00357A61F2013/00927A61K49/223A61M1/0023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,918,880
App. No.
14/252,644
Granted
Mar 20, 2018
Kind
B2
Abstract

Provided is an apparatus that includes a scaffold with a gel or liquid composition deposed on at least a portion of a luminal surface, the gel or liquid composition adapted to include microbubbles. Also provided is a system that includes a source of reduced pressure, the above scaffold, a manifold adjacent the scaffold, and a conduit for providing fluid communication between the manifold and the source of reduced pressure. Additionally provided is a method that includes implanting the above scaffold at the tissue site and disrupting a substantial portion of the microbubbles to induce fluid flow to the scaffold. Further provided is an apparatus that includes a scaffold that comprises a slowly degradable material and a quickly degradable material. Additionally provided is a system for coupling nerve tissue and a microchip assembly.

Claims (15)

1. A method for providing reduced pressure to a tissue site to facilitate tissue growth, the tissue site comprising a gap in the diaphysis of a bone, the method comprising:

providing a scaffold, the scaffold being tubular in shape and having a luminal surface forming at least one channel, the at least one channel at least partially covered by a chemical substance containing microbubbles;

implanting the scaffold in the tissue site so that the at least one channel is in direct fluid communication with an intramedullary space of the tissue site;

providing reduced pressure to the tissue site through the scaffold; and

disrupting a substantial portion of the microbubbles to induce the flow of fluids within the scaffold.

2. The method of claim 1 , wherein the chemical substance forms microbubbles in response to a stimulus that induces a gaseous phase transition in the chemical substance.

3. The method of claim 1 , wherein the microbubbles are pre-formed in the chemical substance.

4. The method of claim 1 , further comprising:

inducing a gaseous phase transition in the chemical substance to form the microbubbles after implanting the scaffold.

5. The method of claim 4 , wherein inducing the gaseous phase transition in the chemical substance includes exposing the chemical substance to the body temperature of the patient.

6. The method of claim 1 , wherein disrupting the substantial portion of the microbubbles includes inducing gradients in the reduced pressure.

7. The method of claim 1 , wherein disrupting the substantial portion of the microbubbles includes inducing directional changes in the reduced pressure by sequentially disrupting the microbubbles across contiguous segments of the scaffold.

8. The method of claim 1 , wherein disrupting the substantial portion of the microbubbles includes exposing the chemical substance to ultrasound energy.

9. The method of claim 1 , wherein disrupting the substantial portion of the microbubbles includes exposing the chemical substance to light energy.

10. The method of claim 1 , wherein the scaffold includes pre-formed low-pressure chambers and the method further comprises rupturing the pre-formed low-pressure chambers.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2015
From: SWAIN, LARRY D.; MANWARING, MICHAEL E.; LEUNG, BRADEN K.; CORNET, DOUGLAS A.
To: KCI LICENSING, INC.
Reel/Frame 034730/0038 →
Continuity (5)
Division 12648448 · Dec 29, 2009
Provisional Application 61234692 · Aug 18, 2009
Provisional Application 61142053 · Dec 31, 2008
Provisional Application 61142065 · Dec 31, 2008
Related Publication 20140276251A1 · Sep 18, 2014